Fig. 9

Analysis of immunotherapy sensitivity and drug screening. (A) Comparison of sensitivity to anti-CTLA-4 and anti-PD-1 inhibitors in low- and high-DCRGS subgroups. (B) Differences in response to chemotherapeutic agents in both subgroups. NR: no response; SD: stable disease; PD: progressive disease; R: response; PR: partial response; CR: complete response. (C) Relationship of the commonly used target genes for LUAD with prognostic genes and DCRGS. (D) Prediction of the drug IC50 in the two subgroups. (E) Correlation between IC50 and DCRGS. The higher the density of dots, the redder the color. “***”: P < 0.001; “****”: P < 0.0001